Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

142.40USD
20 Oct 2017
Change (% chg)

$0.36 (+0.25%)
Prev Close
$142.04
Open
$142.38
Day's High
$143.62
Day's Low
$141.83
Volume
5,634,523
Avg. Vol
5,523,717
52-wk High
$143.62
52-wk Low
$109.32

Latest Key Developments (Source: Significant Developments)

Janssen receives two FDA approvals for SIMPONI ARIA for treatment of active psoriatic arthritis
Friday, 20 Oct 2017 04:23pm EDT 

Oct 20 (Reuters) - Johnson & Johnson :Janssen receives two U.S. FDA approvals for SIMPONI ARIA® (golimumab) for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis.‍Janssen Biotech says U.S. FDA approved SIMPONI ARIA for treatment of adults with active psoriatic arthritis or active ankylosing spondylitis​.  Full Article

Arcturus Therapeutics to collaborate with Johnson & Johnson
Thursday, 19 Oct 2017 07:00am EDT 

Oct 19 (Reuters) - Johnson & Johnson :Arcturus Therapeutics announces strategic collaboration with Johnson & Johnson Innovation to discover and develop RNA medicines.‍arcturus Therapeutics says has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals Inc​.‍arcturus Therapeutics Inc- agreement includes an option to expand into other infectious and respiratory diseases​.‍arcturus Therapeutics - deal was facilitated by Johnson & Johnson innovation center, in California​.‍arcturus Therapeutics - cos to work together to develop and commercialize nucleic acid-based drug products for treatment of Hepatitis B.Arcturus Therapeutics - ‍under agreement, Arcturus will receive an upfront cash payment, research and development support, pre-clinical, development, sales milestone payments​.  Full Article

J&J sets quarterly cash dividend of $0.84 per share
Thursday, 19 Oct 2017 06:50am EDT 

Oct 19 (Reuters) - Johnson & Johnson :Sets quarterly cash dividend of $0.84 per share.  Full Article

Johnson & Johnson Q3 earnings per share $1.37
Tuesday, 17 Oct 2017 06:40am EDT 

Oct 17 (Reuters) - Johnson & Johnson ::Johnson & Johnson reports 2017 third-quarter results.Q3 earnings per share $1.37.Q3 sales $19.7 billion versus I/B/E/S view $19.28 billion.Q3 earnings per share view $1.80 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $7.25 to $7.30.Q3 adjusted non-GAAP earnings per share $1.90 excluding items.Sees FY 2017 sales $76.1 billion to $76.5 billion.Qtrly ‍worldwide pharmaceutical sales of $9.7 billion for Q3 2017 represented an increase of 15.4% versus prior year​.Excluding net impact of acquisitions and divestitures, on operational basis, worldwide, domestic, international sales each increased 3.8% in quarter​.Worldwide medical devices sales of $6.6 billion for Q3 2017 represented an increase of 7.1% versus prior year​.Qtrly ‍worldwide consumer sales of $3.4 billion for Q3 2017 represented an increase of 2.9% versus prior year​.Qtrly worldwide Velcade sales $273‍​ million versus $290 million in Q2 2017.Qtrly worldwide Remicade sales $‍​1,647 million versus $1,530 million in Q2 2017.Qtrly worldwide Zytiga sales $669‍​ million versus $558 million in Q2 2017.Qtrly worldwide Invokana/Invokamet sales $265‍​ million versus $295 million in Q2.Third-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.9 billion​.Third-quarter 2017 net earnings included charge for after-tax special items of approximately $0.5 billion​.  Full Article

Cerveau Technologies announces research collaboration agreement with Janssen Pharmaceuticals
Monday, 16 Oct 2017 02:50pm EDT 

Oct 16 (Reuters) - Cerveau Technologies Inc: :Says announced a research collaboration agreement with Janssen Pharmaceuticals Inc for use of F-18MK-6240​ ‍​.Says collaboration is focused on using F-18MK-6240 as a biomarker in Janssen neurodegenerative disease research studies​.Says parties will collaborate on using F-18MK-6240 to diagnose and evaluate new treatments for neurodegenerative diseases in humans​.  Full Article

Johnson & Johnson says FDA approves Stelara for adolescents with moderate to severe plaque psoriasis
Friday, 13 Oct 2017 04:20pm EDT 

Oct 13 (Reuters) - Johnson & Johnson -:Janssen announces U.S. FDA approval of Stelara® (ustekinumab) for the treatment of adolescents with moderate to severe plaque psoriasis.  Full Article

CHMP issues positive opinion on Janssen’s ZYTIGA
Friday, 13 Oct 2017 07:49am EDT 

Oct 13 (Reuters) - Janssen-Cilag International NV::CHMP issues a positive opinion on Janssen's Zytiga to include earlier stage prostate cancer patients​.  Full Article

Janssen submits NDA for Apalutamide(ARN-509) to FDA
Wednesday, 11 Oct 2017 08:44am EDT 

Oct 11 (Reuters) - Johnson & Johnson :Janssen submits new drug application to U.S. FDA for Apalutamide (ARN-509) to treat men with non-metastatic castration-resistant prostate cancer.Janssen Biotech Inc says submission of the NDA for apalutamide​ is based on Phase 3 data from pivotal ARN-509-003 (SPARTAN) clinical trial.  Full Article

Bayer keeps forecast for peak Xarelto annual sales
Friday, 6 Oct 2017 03:25am EDT 

Oct 6 (Reuters) - Bayer Ag :Says keeps forecast for peak Xarelto annual sales despite new study results‍​.  Full Article

J&J diabetes care company Animas to close operations and exit insulin pump market
Thursday, 5 Oct 2017 07:00am EDT 

Oct 5 (Reuters) - Johnson & Johnson : :‍Johnson & Johnson Diabetes Care Companies - Animas corp intends to discontinue manufacturing, sale of animas vibe and onetouch ping insulin pumps.‍Johnson & Johnson Diabetes Care Companies - Animas corp also intends to close operations and exit insulin pump business​.‍Johnson & Johnson Diabetes Care Companies - Animas selected Medtronic as partner to facilitate transition for patients, caregivers, healthcare providers​.‍Johnson & Johnson Diabetes Care Companies - patients using an Animas insulin pump will be offered option to transfer to a Medtronic pump​.‍Johnson & Johnson Diabetes Care Companies - Johnson & Johnson is continuing to evaluate potential strategic options for Lifescan Inc​.‍Johnson & Johnson Diabetes Care Companies - for patients, healthcare providers outside of U.S., Canada Animas to continue to sell pumps, operate as usual​.  Full Article

Photo

California judge tosses $417 million talc cancer verdict against Johnson & Johnson

A California judge on Friday threw out a $417 million verdict against Johnson & Johnson in a lawsuit by a woman who claimed she developed ovarian cancer after using its talc-based products like Johnson's Baby Powder for feminine hygiene.